Fostroxacitabine bralpamide

Stockholm, Sweden – Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative medical treatments in areas of significant unmet medical need, today announces that its 2025 Annual Report is now available on the company's website, http://www.medivir.com. 2025 was a transformative year for Medivir. In February, final results from the phase 1b/2a study of the fostrox + Lenvima combination in second- or third-line advanced hepatocellular carcinoma (HCC) were presented at the EASL Liver Cancer Summit in Paris. The combination demonstrated a median overall survival of 13.7 months — substantially better than previously reported outcomes in second-line advanced liver cancer. In addition, MIV-711 was granted Orphan Drug Designation by the FDA for the treatment of Osteogenesis Imperfecta, a rare disease for which no approved therapies currently exist. During the year, a rights issue of approximately SEK 151 million was completed, followed by a directed share issue of SEK 45 million to Carl Bennet AB in the beginning of 2025, which secured the funding for the planned Phase 2 studies with fostrox in liver cancer and MIV-711 in Osteogenesis Imperfecta. Medivir also entered into an exclusive license agreement with Canadian-based Biossil, Inc. for remetinostat, with potential milestone payments of up to approximately USD 60 million. In addition, its partner Vetbiolix published groundbreaking clinical Proof-of-Concept results for VBX-1000 (MIV-701) in periodontal disease in dogs. Jens Lindberg, CEO of Medivir, commented: "We have now secured funding for two programs with clear blockbuster potential, both addressing significant unmet medical needs. The randomized, placebo-controlled FLEX-HCC study will generate robust data on fostrox in combination with Lenvima in second-line hepatocellular carcinoma — a setting where no approved treatment options currently exist. At the same time, the directed share issue to Carl Bennet AB enables us to initiate the clinical development of MIV-711 for Osteogenesis Imperfecta, a strategically important new indication for Medivir. We believe both programs have the potential to deliver meaningful value for patients and shareholders alike." The 2025 Annual Report describes the final study results for fostrox + Lenvima and the design of the planned randomized phase 2 FLEX-HCC study, which will be conducted in collaboration with the Korean Cancer Study Group at eight centers in Korea. It provides an overview of the development of MIV-711, including the regulatory advantages conferred by Orphan Drug Designation and the clinical development plan moving forward. The report also covers the out-licensed projects in Medivir's pipeline, including MIV-701, and the progress made during the year. There has been a change in the Group's figures in the Annual Report, which were published in the Q4 report. The intangible assets and equity have been adjusted down by the amount corresponding to the value of MIV-711, as it was not a new project for the Group and should therefore not be included in the Group's financial statements, only in the subsidiary OsteoCat Therapeutics AB, which means that the sale of MIV-711 has still taken place from Medivir AB and the project is recorded in the subsidiary. The change has no impact on Medivir's cash flow, neither in 2025 nor going forward. All of this and much more can be found in Medivir's 2025 Annual Report, published today on the company's website: https://www.medivir.com/investors/reports#FinancialReports2025 This information is information that Medivir is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-04-01 15:00 CEST. For additional information, please contact; Jens Lindberg Chief Executive Officer Medivir AB Phone: +46 8 5468 3100 Email: jens.lindberg@medivir.com About Medivir Medivir develops innovative therapies targeting areas of high unmet medical need. Its drug candidates focus on indications where current treatment options are limited or non-existent, offering the potential to deliver meaningful improvements for patients. Medivir’s two lead programs are fostrox, a precision chemotherapy designed to selectively target liver cancer cells while minimizing side effects, and MIV-711, aimed at treating Osteogenesis Imperfecta (brittle bone disease). Both candidates have blockbuster potential, representing significant value creation opportunities for Medivir’s shareholders and affected patients. Collaborations and partnerships play a key role in Medivir’s business model, with drug development conducted either in-house or in partnership. Medivir (Nasdaq Stockholm: MVIR) is listed on the Small Cap segment of Nasdaq Stockholm. More information is available at www.medivir.com Attachments Medivir Annual Report 2025

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative medical treatments in areas of high unmet medical need, announced today the formation of a Scientific Expert Council as the company intensifies its plans for next phase of development with MIV-711 in Osteogenesis Imperfecta. In February, Medivir announced its intention to initiate clinical development of its proprietary drug candidate MIV-711 for the treatment of Osteogenesis Imperfecta (OI), a rare bone disease with significant unmet medical need and no approved disease-modifying therapies. This new and strategically important investment in MIV-711 for OI is supported by the directed share issue to Carl Bennet AB, which raised SEK 45 million. The program has the potential to address a market opportunity of at least USD 2.5 billion, comparable to fostrox in primary liver cancer. MIV-711 was granted Orphan Drug Designation by the US Food and Drug Administration (FDA) in November 2025, providing important benefits, including market exclusivity following approval. As the company accelerates preparations to initiate a clinical study in OI, with the objective of establishing clinical proof-of-concept, the Scientific Expert Council will work closely with Medivir to provide strategic guidance and expertise on study design and execution, while also helping lay the foundation for the next phase of clinical development. - “Having the possibility to learn about OI from a vastly experienced and highly renowned Scientific Expert Council ensures a vital foundation for designing and executing a clinical program in a rare disease. I am truly honored that we have been able to attract some of the world's leading experts in Osteogenesis Imperfecta to our Scientific Advisory Council, whose expertise and deep clinical knowledge will be critical in moving the clinical development of MIV-711 forward,” says Dr. Pia Baumann, Chief Medical Officer at Medivir. - “For patients living with Osteogenesis Imperfecta, the burden of recurrent fractures and progressive skeletal fragility remains profound, and current therapies fall short of addressing the underlying mechanisms that drive disease progression. There is a critical need for treatments that can directly influence bone remodeling and improve structural integrity, rather than simply managing symptoms. Cathepsin K inhibition represents a promising approach, targeting a key enzyme involved in excessive bone resorption, with the potential to strengthen bone and reduce fracture rates. Advancing this type of therapy could mark an important step toward meeting the significant unmet medical need faced by the OI community,” says Dr. Andreas Kindmark, Uppsala University Hospital. Members of Medivir’s Scientific Advisory Council: Dr. Marelise Eekhoff is an internist‑endocrinologist and professor at Amsterdam UMC, where she leads the center for rare bone disorders, including Osteogenesis Imperfecta, Fibrodysplasia Ossificans Progressiva, Genetic Osteoporosis, Fibrous Dysplasia/MAS, and Camurati‑Engelmann among others. She is a highly active researcher and has contributed extensively to scientific literature spanning rare skeletal diseases, pre‑ and clinical pathophysiology, treatment, and clinical management. She is responsible for a significant number of clinical studies. Dr. Richard Keen is a Consultant Rheumatologist and Director, Centre for Metabolic Bone Disease at Royal National Orthopaedic Hospital, Stanmore, UK. He specialises in clinical research and development of novel therapies for adults with rare metabolic bone conditions. He is the Chair of the UK Brittle Bone Society's Scientific Advisory Board. He has published over 60 scientific papers in peer-reviewed journals. Dr. Andreas Kindmark is an Associate Professor and Senior Consultant in Endocrinology at Uppsala University Hospital. He is clinically active at the Metabolic Diseases Clinic, specializing in the investigation of skeletal metabolic disorders, and is heading the Uppsala University Hospital units for National Highly Specialized care for Osteogenesis Imperfecta and for Skeletal Dysplasias. Dr Kindmark is also responsible for the Uppsala University Hospital DXA unit at the department of radiology. His research interests span from epidemiological studies, through effects of hereditary factors influencing bone metabolism, and he heads a research group working to identify genes and genetic variants affecting bone health. Dr. Bente Langdahl is a clinical professor, Department of Endocrinology and Internal medicine, Aarhus University Hospital, Denmark. She specializes in metabolic bone disorders with particular focus on Osteoporosis and Osteogenesis Imperfecta. She is head of the Clinical Bone Research Center at Aarhus University Hospital. She has authored more than 300 peer‑reviewed scientific papers, contributing extensively to the understanding of Osteoporosis, rare bone diseases including Osteogenesis Imperfecta and genetics of bone disorders. Dr. Oliver Semler is a pediatrician and professor at the University of Cologne, where he leads the department for rare skeletal diseases in childhood. His clinical and research work focuses on Osteogenesis Imperfecta and other skeletal dysplasias.A highly active researcher, he has contributed extensively to the scientific literature, with numerous publications spanning OI pathophysiology, treatment, and clinical management. For additional information, please contact; Jens Lindberg Chief Executive Officer Medivir AB Phone: +46 8 5468 3100 Email: jens.lindberg@medivir.com About Osteogenesis Imperfecta Osteogenesis imperfecta (OI), also known as brittle bone disease, is a rare and hereditary disorder characterised by fragile bones with a high susceptibility to fractures. The disease is caused by various genetic mutations that affect the structure or production of the bone matrix. The severity varies from mild to very severe forms. The most severe cases can involve repeated fractures, skeletal deformities, pain and short stature, and in the most severe form, children do not survive infancy. Globally, an estimated 500,000 people are affected, of whom around 135,000 are children. OI often requires lifelong treatment, with the aim of improving quality of life and reducing the risk of fractures. About MIV-711 MIV-711 is a potent and selective inhibitor of cathepsin K, the main protease involved in breaking down collagen in bone and cartilage. It has been shown to slow, stop or reverse the progressive degeneration of joints affected by osteoarthritis. By inhibiting cathepsin K and increased/excessive osteoclast activity, MIV-711 has the potential to counteract the excessive bone breakdown seen in patients with Osteogenesis Imperfecta (brittle bone disease). MIV-711 restores the balance between the breakdown of bone with mutated collagen and the formation of new bone with the aim of preventing fractures and bone deformities. About Medivir Medivir develops innovative therapies targeting areas of high unmet medical need. Its drug candidates focus on indications where current treatment options are limited or non-existent, offering the potential to deliver meaningful improvements for patients. Medivir’s two lead programs are fostrox, a precision chemotherapy designed to selectively target liver cancer cells while minimizing side effects, and MIV-711, aimed at treating Osteogenesis Imperfecta (brittle bone disease). Both candidates have blockbuster potential, representing significant value creation opportunities for Medivir’s shareholders and affected patients. Collaborations and partnerships play a key role in Medivir’s business model, with drug development conducted either in-house or in partnership. Medivir (Nasdaq Stockholm: MVIR) is listed on the Small Cap segment of Nasdaq Stockholm. More information is available at www.medivir.com Attachments Press Release (PDF)